Increase in the circulating level of hepatocyte growth factor in gastric cancer patients
1997

Hepatocyte Growth Factor Levels in Gastric Cancer Patients

Sample size: 208 publication Evidence: moderate

Author Information

Author(s): T Taniguchi, M Kitamura, K Arai, Y Iwasaki, Y Yamamoto, A Igari, M Toil

Primary Institution: Tokyo Metropolitan Komagome Hospital

Hypothesis

The study investigates the significance of serum hepatocyte growth factor (HGF) levels as a tumor marker in gastric cancer patients.

Conclusion

Elevated serum HGF levels are associated with tumor progression in gastric cancer, suggesting its potential as a tumor marker.

Supporting Evidence

  • Serum HGF levels were significantly higher in patients with recurrent gastric cancer compared to healthy controls.
  • 33.7% of primary gastric cancer patients showed elevated HGF levels.
  • HGF levels were significantly associated with the degree of histological tumor invasion.
  • 14 out of 15 patients with recurrent gastric cancer exhibited elevated HGF levels.

Takeaway

This study found that many gastric cancer patients have higher levels of a substance called HGF in their blood, which might help doctors understand how advanced the cancer is.

Methodology

Serum HGF levels were measured using an enzyme-linked immunosorbent assay (ELISA) in patients with primary and recurrent gastric cancer, compared to healthy controls.

Limitations

The study did not examine intratumoral HGF concentrations in gastric cancer tissues.

Participant Demographics

104 patients with primary gastric cancer (74 men, 30 women) and 15 patients with recurrent gastric cancer, average age 64.0 years; 89 healthy controls (47 men, 42 women), average age 49.7 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication